After hearing that an independent safety board raised concerns about late stage data on Gentium's drug Defibrotide, investors shaved off about 30 percent of its stock's value this morning. The board didn't make any recommendation, however, and the company says it's considering its next steps. The independent Data Safety Monitoring Board "did not regard it proper to make a recommendation concerning the further conduct of the study," the company said.
One analyst noted significant frustration with the development, noting that it raises questions about the future of the drug. The drug is being tested as a treatment for veno-occlusive disease in stem-cell transplant patients.
- read the AP story